Video Series

Richard Adler, MD, FACS, provides insights on data presented at AA0 2023, from a study comparing results of the ARMOR procedure versus treatment with cyclosporine ophthalmic emulsion 0.05% in patients with dry eye disease.

Richard Adler, MD, FACS, discusses corneal fluorescein staining data presented at AAO 2023 from the pooled analysis of 2 phase 3 studies.

Richard Adler, MD, FACS, leads a discussion on real-world signs, symptoms and patient reactions associated with the treatment for DED.

Deborah Stephens, DO, shares unmet needs in the current treatment landscape of CLL and SLL.

A panel of experts explore current treatment strategies in CLL and SLL management.

Clinical manifestations and impact on patient quality of life amid diagnosis and management of CLL and SLL are discussed.

Richard Adler, MD, FACS, discusses the Switch trial which compared OTX-101 (cyclosporine ophthalmic solution 0.09%) vs cyclosporine ophthalmic emulsion 0.05% (Restasis) in patients with dry eye disease (DED).

The panel provides closing thoughts on the future of the CSCC and BCC treatment landscape.

Exploring recent trials and updates in nonmelanoma skin cancer treatment.

Experts discuss advancements in imaging techniques and risk factors associated with desmoid tumors, emphasizing the importance of accurate evaluation and management decisions.

Experts provide insights on recent ICD-10 code availability for desmoid tumors, its implications on diagnosis, treatment, and coverage decisions, as well as the significance for research, patient care, and health care management strategies.

Aaron Gerds, MD, MS, compares myelofibrosis with other myeloproliferative neoplasms, explores its prevalence in the US, and reviews the diverse clinical presentations and the impact on patients’ quality of life.

Key considerations for transitioning patients receiving bispecific therapy between care settings are highlighted.

The panelists discuss 24/7 bispecific care protocols for urgent healthcare needs.

An overview of the current landscape of available treatment options for Demodex blepharitis is analyzed.

Dr Metersky provides an overview of current treatment strategies for managing patients diagnosed with bronchiectasis.

Amy Nguyen Howell, MD, MBA, delves into strategies for health care systems to ensure equitable access and treatments for marginalized individuals with diabetic macular edema.

Health care professionals delve into discussions on using quadruplets in multiple myeloma treatment, addressing challenges, and considerations for high-risk patients.

Mirna Chehade, MD, MPH, emphasizes the value of proton pump inhibitors, swallowed corticosteroids, and dietary restrictions as therapeutic options for pediatric patients with eosinophilic esophagitis (EoE), while underscoring the importance of shared decision-making to maintain adherence and achieve better outcomes.

Experts discuss challenges in induction regimens for transplant-ineligible myeloma patients, and evolving approaches, quad regimens, dynamic frailty, and upcoming trials shaping future treatment options.

Experts explore the evolving goals in treating newly diagnosed patients with multiple myeloma, including balancing effective therapies, achieving MRD-negative remission, and managing toxicities.

Key opinion leaders share their final thoughts on advancing treatments of Dry Eye Disease.

A professional analysis of the potential cost-effective impact of emerging dry eye therapies on the health care system.

Medical professionals explore CSCC and BCC treatment in high-risk, immunocompromised patients—specifically in the setting of organ transplantation.

Experts explore the socioeconomic impact of CSCC and BCC, and which late-stage patients will derive the greatest benefit from hedgehog inhibitors, immunotherapies, and other emerging treatments.

Medical experts dissect critical strategies for monitoring for potential adverse events with bispecific antibodies in a comprehensive panel discussion.

Practical guidance for institutions navigating bispecific therapy integration without prior experience is provided.

Mirna Chehade, MD, MPH, outlines consequences that can stem from delay in diagnosis of eosinophilic esophagitis (EoE), as well as treatment goals, highlighting unique considerations for treatment in children.

Experts provide insights for health care decision makers on the importance of Lp(a) level assessment to help mitigate the risk of cardiovascular disease, including actionable steps for seamless integration.

Michael D. Shapiro, DO, and Erin D. Michos, MD, MHS, provide insights into upcoming Lp(a)-targeted treatments and current management strategies for improved cardiovascular outcomes.